Faron Pharmaceuticals Limited (AIM:FARN, OTC:FPHAF) is to present updated Phase 1/2 data from its ongoing BEXMAB study of bexmarilimab at the 65th American Society of Hematology (ASH) Annual Meeting.
The ASH Annual Meeting will take place from 9-12 December 2023, in San Diego, California and virtually.